← Leaderboards
Ronald J. Ellis
University Of California, San Diego
$34,493,757
Attributed
$47,247,550
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,747,532 · 20
By mechanism
R01$30,301,685 · 8
P30$10,487,800 · 5
R24$7,973,681 · 1
RF1$1,548,394 · 1
P01$580,626 · 1
M01$384,491 · 2
Top collaborators
- Scott L Letendre11 shared
- Brook Henry8 shared
- Jared William Young5 shared
- Fred R Sattler4 shared
- David J Moore3 shared
- Michael Phillip Dube2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Scott L Letendre$25,948,231
- Brook Henry$8,903,411
- Arpi Minassian$3,527,634
- Jared William Young$14,211,149
- Gabriel Arturo Wagner$813,024
Others in their field
Top investigators on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$297,689,086
- Lawrence Corey · Fred Hutchinson Cancer Center$297,689,086
- David R. Weir · University Of Michigan At Ann Arbor$286,732,935
- Jeffrey P Krischer · University Of South Florida$271,114,178
- David Heimbrook · Leidos Biomedical Research, Inc.$227,381,786
Research focus
Biological MarkersAntiretroviral TherapyPersonsInflammationParticipantViralCerebrospinal FluidResearch PersonnelHiv InfectionsClinical TrialsFutureFundingCognitiveBaseCognitionNeurocognitiveSamplingNeurologicNeurobehavioralLinkImpairmentComorbidityNeurocognitive DeficitClinical Research
Grant awards (80)
CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan$1,968,823
R24 · FY2025 · MH
GPLD1: Association with Cognition and Amelioration through Exercise in Aging People with HIV$1,548,394
RF1 · FY2025 · AG · contact PI
HIV Neurobehavioral Research Center$1,499,994
P30 · FY2025 · MH
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV$896,116
R01 · FY2025 · DA · contact PI
Immunometabolicgene expression profiles associated with depressed mood and behavioral domains inpeople with HIV$696,003
R01 · FY2025 · MH · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$603,658
R01 · FY2025 · MH
NeuroMedical Core$350,871
P30 · FY2025 · MH · contact PI
CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan$1,980,078
R24 · FY2024 · MH
HIV Neurobehavioral Research Center$1,499,994
P30 · FY2024 · MH
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV$896,116
R01 · FY2024 · DA · contact PI
GPLD1: Association with Cognition and Amelioration through Exercise in Aging People with HIV$789,997
R01 · FY2024 · AG · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$710,186
R01 · FY2024 · MH
Immunometabolicgene expression profiles associated with depressed mood and behavioral domains inpeople with HIV$696,003
R01 · FY2024 · MH · contact PI
NeuroMedical Core$350,870
P30 · FY2024 · MH · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$122,093
R01 · FY2024 · MH
CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan$1,971,786
R24 · FY2023 · MH
HIV Neurobehavioral Research Center$1,499,994
P30 · FY2023 · MH
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV$896,116
R01 · FY2023 · DA · contact PI
GPLD1: Association with Cognition and Amelioration through Exercise in Aging People with HIV$789,997
R01 · FY2023 · AG · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$710,186
R01 · FY2023 · MH
Immunometabolicgene expression profiles associated with depressed mood and behavioral domains inpeople with HIV$696,003
R01 · FY2023 · MH · contact PI
NeuroMedical Core$350,871
P30 · FY2023 · MH · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$40,698
R01 · FY2023 · MH
CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan$2,052,994
R24 · FY2022 · MH
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids and Neuroinflammation in HIV$896,116
R01 · FY2022 · DA · contact PI
GPLD1: Association with Cognition and Amelioration through Exercise in Aging People with HIV$789,997
R01 · FY2022 · AG · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$710,186
R01 · FY2022 · MH
Immunometabolicgene expression profiles associated with depressed mood and behavioral domains inpeople with HIV$696,003
R01 · FY2022 · MH · contact PI
NeuroMedical Core$350,871
P30 · FY2022 · MH · contact PI
Immunometabolicgene expression profiles associated with depressed mood and behavioral domains inpeople with HIV$786,497
R01 · FY2021 · MH · contact PI
Biopsychosocial Phenotypes and Potential Mechanisms in CHARTER$758,817
R01 · FY2021 · MH
NeuroMedical Core$337,141
P30 · FY2021 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$741,150
R01 · FY2020 · AG · contact PI
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain$594,681
R01 · FY2020 · DA
NeuroAssessment Core$496,381
P30 · FY2020 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$646,035
R01 · FY2019 · AG · contact PI
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain$602,874
R01 · FY2019 · DA
NeuroAssessment Core$496,381
P30 · FY2019 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$640,315
R01 · FY2018 · AG · contact PI
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain$604,788
R01 · FY2018 · DA
NeuroAssessment Core$496,665
P30 · FY2018 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$640,095
R01 · FY2017 · AG · contact PI
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain$618,199
R01 · FY2017 · DA
NeuroAssessment Core$496,701
P30 · FY2017 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$641,612
R01 · FY2016 · AG · contact PI
NeuroAssessment Core$496,381
P30 · FY2016 · MH · contact PI
NeuroAssessment Core$1
P30 · FY2016 · MH · contact PI
Phase II trial of tesamorelin for cognition in aging HIV-infected persons$659,438
R01 · FY2015 · AG · contact PI
Intrahost HIV population dynamics in CNS and other tissues$398,040
R01 · FY2015 · MH · contact PI
Neuromedical Core (Page 348)$353,620
P30 · FY2015 · MH · contact PI
Intrahost HIV population dynamics in CNS and other tissues$398,009
R01 · FY2014 · MH · contact PI
Neuromedical Core (Page 348)$350,447
P30 · FY2014 · MH · contact PI
Building research capacity in aging HIV-infected persons$70,300
R03 · FY2014 · AG · contact PI
Intrahost HIV population dynamics in CNS and other tissues$398,003
R01 · FY2013 · MH · contact PI
Neuromedical Core (Page 348)$339,245
P30 · FY2013 · MH · contact PI
Building research capacity in aging HIV-infected persons$84,050
R03 · FY2013 · AG · contact PI
Neuromedical Core (Page 348)$357,903
P30 · FY2012 · MH · contact PI
Neuromedical Core (Page 348)$10,001
P30 · FY2012 · MH · contact PI
Neuromedical Core (Page 348)$353,468
P30 · FY2011 · MH · contact PI
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART$1,213,292
R01 · FY2010 · MH · contact PI
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART$1,253,879
R01 · FY2009 · MH · contact PI
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART$1,229,392
R01 · FY2008 · MH · contact PI
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART$1,250,801
R01 · FY2007 · MH · contact PI
HIV Clade on Cognitive and Neurological Disorders Brazil$136,853
R21 · FY2007 · MH · contact PI
MEDICINAL CANNABIS IN PAINFUL HIV NEUROPATHY$100,345
M01 · FY2007 · RR · contact PI
HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART$1,053,952
R01 · FY2006 · MH · contact PI
HIV Clade on Cognitive and Neurological Disorders Brazil$179,652
R21 · FY2006 · MH · contact PI
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$156,813
R01 · FY2006 · MH · contact PI
MEDICINAL CANNABIS IN PAINFUL HIV NEUROPATHY$129,020
M01 · FY2006 · RR · contact PI
MEDICINAL CANNABIS IN PAINFUL HIV NEUROPATHY$89,953
M01 · FY2005 · RR
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$703,610
R01 · FY2004 · MH
Medicinal Cannabis in Painful HIV Neuropathy$65,173
M01 · FY2004 · RR
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$683,289
R01 · FY2003 · MH
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$723,260
R01 · FY2002 · MH
NeuroAIDS: Cerebrospinal fluid$124,146
P01 · FY2002 · DA
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$644,064
R01 · FY2001 · MH
NeuroAIDS: Cerebrospinal fluid$124,146
P01 · FY2001 · DA
HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AND CHEMOKINES$625,306
R01 · FY2000 · MH
NeuroAIDS: Cerebrospinal fluid$208,188
P01 · FY2000 · DA
NeuroAIDS: Cerebrospinal fluid$124,146
P01 · FY2000 · DA